X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SANOFI INDIA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SANOFI INDIA FRESENIUS KABI ONCO./
SANOFI INDIA
 
P/E (TTM) x 22.1 30.0 73.8% View Chart
P/BV x 3.1 5.3 58.8% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 FRESENIUS KABI ONCO.   SANOFI INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SANOFI INDIA
Dec-16
FRESENIUS KABI ONCO./
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1764,560 3.9%   
Low Rs794,400 1.8%   
Sales per share (Unadj.) Rs37.71,028.5 3.7%  
Earnings per share (Unadj.) Rs5.1129.0 3.9%  
Cash flow per share (Unadj.) Rs6.7186.0 3.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs42.5753.6 5.6%  
Shares outstanding (eoy) m158.2323.03 687.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.5%   
Avg P/E ratio x25.034.7 71.9%  
P/CF ratio (eoy) x18.924.1 78.6%  
Price / Book Value ratio x3.05.9 50.3%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m20,135103,174 19.5%   
No. of employees `0001.23.6 31.8%   
Total wages/salary Rs m7033,592 19.6%   
Avg. sales/employee Rs Th5,176.26,537.7 79.2%   
Avg. wages/employee Rs Th610.4991.4 61.6%   
Avg. net profit/employee Rs Th699.6819.8 85.3%   
INCOME DATA
Net Sales Rs m5,96323,686 25.2%  
Other income Rs m18708 2.5%   
Total revenues Rs m5,98124,394 24.5%   
Gross profit Rs m1,4305,281 27.1%  
Depreciation Rs m2581,313 19.6%   
Interest Rs m-2615 -173.3%   
Profit before tax Rs m1,2164,661 26.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,691 20.2%   
Profit after tax Rs m8062,970 27.1%  
Gross profit margin %24.022.3 107.6%  
Effective tax rate %28.136.3 77.6%   
Net profit margin %13.512.5 107.8%  
BALANCE SHEET DATA
Current assets Rs m5,10215,673 32.6%   
Current liabilities Rs m2,3856,678 35.7%   
Net working cap to sales %45.638.0 119.9%  
Current ratio x2.12.3 91.1%  
Inventory Days Days15076 197.4%  
Debtors Days Days11322 507.7%  
Net fixed assets Rs m5,1488,098 63.6%   
Share capital Rs m158230 68.7%   
"Free" reserves Rs m6,55617,088 38.4%   
Net worth Rs m6,73217,356 38.8%   
Long term debt Rs m9520-   
Total assets Rs m10,38825,400 40.9%  
Interest coverage x-45.8311.7 -14.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 61.6%   
Return on assets %7.511.8 63.9%  
Return on equity %12.017.1 70.0%  
Return on capital %14.626.9 54.2%  
Exports to sales %74.524.5 304.1%   
Imports to sales %24.828.0 88.6%   
Exports (fob) Rs m4,4415,801 76.5%   
Imports (cif) Rs m1,4776,627 22.3%   
Fx inflow Rs m5,2987,145 74.1%   
Fx outflow Rs m1,7726,846 25.9%   
Net fx Rs m3,525299 1,179.1%   
CASH FLOW
From Operations Rs m1,2743,226 39.5%  
From Investments Rs m-1,204-1,555 77.4%  
From Financial Activity Rs m-196-1,818 10.8%  
Net Cashflow Rs m-126-147 85.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 60.4 134.1%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 9.6 14.6 65.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 15,184 280.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - GLENMARK PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS